Arabic Arabic English English French French German German
dark

Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH

Theratechnologies, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported financial results for the second quarter ended May 31, 2021 and provided an update on its planned Phase 3 clinical trial evaluating tesamorelin for the treatment of nonalcoholic steatohepatitis. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

White House Enlists Social Media Giants to Suppress Vaccine ‘Misinformation’

Next Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Related Posts
Total
0
Share